NeuroVive Out-licenses Targeted LHON Therapy To BridgeBio Pharma's New Subsidiary Fortify Therapeutics

Monday, June 18, 2018 1 min read

Key Takeaway: NeuroVive Out-licenses Targeted LHON Therapy To BridgeBio Pharma's New Subsidiary Fortify Therapeutics

Full Press Release Details

NeuroVive Out-licenses Targeted LHON Therapy To BridgeBio Pharma's New Subsidiary Fortify Therapeutics.